Venom research is a large field, especially due to the pharmaceutical potential of the venom proteins. The idea here is that venom proteins are capable of affecting the body's cells. Excessive amounts can be harmful and even lethal in some circumstances, but if the right dose is used, the venom proteins can be used to treat certain diseases. Snake proteins that normally cause prey to bleed can be used in small doses to treat blood clots, for example.

In the same way, work is currently being done to develop spider venom proteins to provide pain relief. The Aarhus researchers focused on gila lizards, and these are currently being used in pharmaceutical contexts. Gila lizards produce exendin-4, a small venom protein used in the treatment of diabetes and obesity, which is a competitor to Victoza - produced by Novo Nordisk.